Therefore, medical treatment of DCM, as with medications for heart failure, aims to be significant clinical benefits such as improved survival and reduce rehospitalization rates, including angiotensin receptor-neprilysin inhibitor, angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), beta-adrenoreceptor blockers (BB), aldosterone antagonists.[4] Despite the extensive phenotype and complex pathophysiology of DCM, ischemic heart disease remains the predominant cause. This evidence concerns the gene MME and familial dilated cardiomyopathy.